Citations 31
Diagnostic value of aquaporin-4-IgG live cell based assay in neuromyelitis optica spectrum disorders
Redenbaugh, Vyanka , Montalvo, Mayra , Sechi, Elia , Fryer, James P., Lennon, Vanda A. , Mills, John R. , Wingerchuk, Dean M. , Chen, John J. , Bhatti, M. Tariq , López‐Chiriboga, A. Sebastian , Pittock, Sean J, Pittock, Sean J. , Lopez-Chiriboga, A Sebastian , Pittock, Sean J , Flanagan, E P , Pittock, S J , Chen, John J , Sechi, Elia , Redenbaugh, Vyanka , Buciuc, Marina , McKeon, Andrew , Weinshenker, Brian G. , Flanagan, Eoin P.
Multiple Sclerosis Journal - Experimental, Translational and Clinical | November 26, 2021 | Volume: 7 | Issue: 4 | Pages: No page available
Objective Determine the utility of aquaporin 4 IgG (AQP4-IgG) testing (live cell-based assay) for Neuromyelitis Optica Spectrum Disorders (NMOSD). Methods We included Mayo Clinic patients (1/1/2018-12/31/2019) tested for serum AQP4-IgG by live cell-based flow-cytometric assay. Medical records were reviewed to assess if patients fulfilled 2015 NMOSD criteria. Results Of 1371 patients tested, 41 were positive (3%) and all fulfilled NMOSD criteria with AQP4-IgG (specificity = 100%). Only 10/1330 testing negative met NMOSD criteria without AQP4-IgG (sensitivity = 80%) and seven of these 10 were MOG-IgG positive. Conclusions AQP4-IgG by live cell-based assay was highly specific and without false positives in a high throughput setting.